ambert-Eaton myasthenic syndrome: Clinical characteristics, pathogenesis and tumour associatio
Recruiting
- Conditions
- LEMS100038161002931710029107
- Registration Number
- NL-OMON40297
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
Diagnosis of LEMS
Criterion 1 and 2 or 1 and 3 have to be fulfilled
1. Clinical features consistent with LEMS (proximal muscle weakness, reduced tendon reflexes, autonomic symptoms)
2. Abnormalities upon repetitive nerve stimulation (decrement of CMAP amplitude and/or increment after voluntary contraction or high frequency stimulation)
3. Presence of VGCC antibodies;Diagnosis of SCLC
Definitive diagnosis of SCLC based on pathology results (either cytology or histology).
Exclusion Criteria
* Age < 18 years
* Unable to give informed consent
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Description of epidemiology, clinical characteristics and disease course in<br /><br>LEMS patients.<br /><br>Comparison of the humoral and cellular immune response in LEMS patients and<br /><br>SCLC patients with and without LEMS. </p><br>
- Secondary Outcome Measures
Name Time Method <p>- Tumour size on lung imaging studies and growth rate upon follow-up.<br /><br>- DELTA-P score tumor prediction score in LEMS patients, diagnosis of SCLC upon<br /><br>follow-up<br /><br>- Presence of other auto-antibodies possibly related to LEMS<br /><br>- Tumour infiltration of SCLC by lymphocytes and macrophages (+- LEMS)<br /><br>- Anti-tumour effect of serum VGCC antibodies and related macrophage and<br /><br>adaptive response in vitro<br /><br>- Presence of specific T cells against tumour-related antigens<br /><br>- Patients' experience with symptomatic medication for LEMS</p><br>